Clinical Trial of Pioglitazone Treatment in Patients With Type 2 Diabetes Mellitus and Covid-19
Status:
Recruiting
Trial end date:
2021-04-10
Target enrollment:
Participant gender:
Summary
The treatment with pioglitazone added to the standard treatment of patients with DM2
hospitalized for COVID-19 may produce a decrease in the number of patients who progress to a
second phase of severe systemic inflammation.
Phase:
Phase 4
Details
Lead Sponsor:
Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal